Top Tech Companies (719)
Don't see your company?
Create a company profile
Dauntless Pharmaceuticals is a biotechnology company that focuses on the development of drugs.
At Enable Medicine, we index biological data into highly detailed maps of human disease. This atlas is utilized to guide novel drug target discovery, identify biomarkers of therapeutic response, and develop optimal treatment strategies. Our lab in Menlo Park, California, generates high-parameter biological datasets, and our cloud-based operating system allows researchers to organize, process, query, and analyze this data at scale. Taken together, our platform unlocks the ability to search biology, where complex questions about human disease can be asked and answered for the first time. We build and provide these capabilities to our network of leading academic institutions and pharmaceutical companies around the world. Our collaborative research spans numerous indications, with a core focus on unmet needs in oncology and autoimmune diseases. We advance science by accelerating data generation, methods development, research insights, and high-impact publications. Our interdisciplinary team of scientists, engineers, researchers, and investors focuses on decoding biological systems to make drug discovery, development, and patient care more deterministic. Come join us on our mission to decipher biology and meaningfully improve the way patients are treated.
SpotRx is a full-service pharmacy designed around our patients' needs. We leverage innovative technology to create one of a kind services that take patient care to a new level. We are focused on providing; greater medication access, competitive medication pricing, and real-time access to a pharmacist. SpotRx’s parent company, MedAvail Technologies Inc., has a proven track record as a healthcare technology company that has developed and commercialized the innovative self-service pharmacy, mobile app, kiosk and drive-thru solution SpotRx utilizes to provide you with unparalleled availability to the medications you need.
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
PharmaEssentia Corporation is a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product approved in The United States and a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with limited options today through the combination of rigorous research and innovative thinking. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today we are listed on the Taipei Exchange (TPEx: 6446) and are expanding our global presence with operations in the U.S., Japan, South Korea and China, along with a world-class biologics production facility in Taichung. See our community guidelines: bit.ly/PECcommunity
myMatrixx provides pharmacy benefits management, ancillary benefits management, and clinical management for workers' compensation programs.
Two Labs, founded in 2003 and headquartered in Columbus, Ohio, has offices and operations across the US and UK and is a leading pharmaceutical services company that partners with pharma/biotech companies. At Two Labs, we understand no two product paths are alike. We deliver integrated and customized commercial solutions, helping to chart the path from clinical to commercial for a new product launch and provide strategies for continued market viability for drugs on the market. Two Labs has a proven track record of successful launches across all major therapeutic areas with unmatched client satisfaction. Since 2003, we have supported more than 200+ new product launches and more than 230+ in-market projects from pre-launch to loss of exclusivity. . In 2018, Two Labs expanded its presence in the pharma consulting space with the acquisition of MKO Global Partners, our Market Access team, a strategic global life sciences consulting team of experts in pricing and market access space; and Pennside Partners, our Market Intelligence Team, who has been in the Competitive Intelligence space for over 25 years. In 2020, we added the talent of CEEK Enterprises, our Strategic Consulting Team, who specializes in pharma management consultancy and who has worked with several leading biopharmaceutical and medical technology companies. Coupled with our rapid organic growth, these acquisitions allow us to provide a larger portfolio of pharma services throughout the product lifecycle and help pharma companies and patients more than ever. Two Labs is a highly collaborative, friendly, passionate, and energized team of professionals who work in an environment that goes beyond casual dress and flex scheduling. No structure or formality is permitted to get in the way of collaboration and teamwork. The ongoing growth of the company offers team members continuous opportunities to gain experience, develop skills and chart their course along an exciting success path.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy
Cmxtwenty focuses on developing lipid compounds for use in non-narcotic pain treatment.
.jpeg)
.png)
Ingenus Pharmaceuticals is an emerging privately held U.S. based generic pharmaceutical company with manufacturing and research and development facilities in the U.S.,Switzerland, and India. Since 2010, Ingenus has been developing, manufacturing and commercializing quality generic medications as cost effective solutions for patients and suppliers. With over 65 filings covering a wide range of therapeutic classes ,including transdermal, parenteral, semi-solids, injectable, and extended release products Ingenus is well positioned to becoming a leader in the generic pharmaceutical industry.
KeySource (KeySource Acquisition, LLC) supplies the generic pharmaceutical needs of end-user pharmacies across the United States. Our professionally trained and knowledgeable sales force is focused on serving the interests of our customers, building relationships, emphasizing the highest level of service, integrity and value. Our Account Managers facilitate orders and keep our customers informed of industry news and ongoing developments. KeySource distributes thousands of products daily from our Ohio based, VAWD® accredited, distribution center. Our internal culture and industry experience have allowed us to grow by delivering innovative solutions to our customers while adhering to the highest standard of product security. As we look to the future, we remain dedicated to providing unparalleled service to our customers, paving the way with our customer first approach. • KeySource purchases ALL products it sells directly from FDA approved manufacturers. • KeySource has received VAWD (Verified-Accredited Wholesale Distributor) accreditation from the National Association of Boards of Pharmacy. • KeySource is an active member of HDMA (Healthcare Distribution Management Association), a National Association comprised of America’s largest pharmaceutical distributors
Med Communications is dedicated to delivering high-quality medical affairs, pharmacovigilance, and commercial solutions
Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.
Femta Pharmaceuticals is a biotechnology company that develops protein therapeutics.
TheraTarget is led by world-renown experts in polymer-drug chemistry.
Anaphore is developing protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. RuiYi is a Wholly Foreign-Owned Enterprise (WFOE) located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China. RuiYi is developing biologic therapies that target G protein coupled receptors (GPCRs).
At the heart of iA, we are passionate about pharmacy. Everything we do is designed to enable pharmacists to make a difference in the health and wellbeing of their patients. With over 25 years in the pharmacy fulfillment business, we have invented and developed a suite of leading-edge software enabled pharmacy fulfillment solutions. From our intelligent Pharmacy Operations Software Platform, to our modular and sophisticated counting and collation devices and our strategic partners, iA can run the prescription fulfillment process from end-to-end, helping pharmacies manage fulfillment and inventory to help lower costs, improve efficiency, and provide comprehensive Rx tracking and real-time support. For centralized fulfillment or pharmacy operations, let us focus on your prescription fulfillment so your pharmacists can focus on patient-facing care. iA is unleashing the full potential of pharmacy
Aktiv Pharma Group brings peace of mind to people at risk and their communities by developing simple-to-use emergency treatment technologies. Initially developed for the military, the ARAI™ is a prefilled auto-injector that uses single-hand, single-step activation. Now, ARAI is being developed to help people with life-threatening conditions in emergency situations, such as hypoglycemia, anaphylaxis and opioid overdose. Aktiv's platform technology has been used in a variety of form factors—including pre-filled syringes, auto-injectors, oral and topical dispensers, and IV transfer systems—which serve a broad range of medical applications. The flexible platform can be configured to carry a single drug solution or individually store multiple drug constituents that are either injected separately or automatically mixed just prior to injection. To learn more about career or investment opportunities, please visit www.aktivax.com.
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
